aweinsoff@channelchek.com, Author at Channelchek

Release – Lucibeth N. Mayberry Named President and CEO and Director of CoreCivic Patrick D. Swindle Steps Down Due to Health Reasons

Posted on September 25, 2026September 25, 2026 by [email protected]

September 25, 2026

BRENTWOOD, Tenn., Sept. 25, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic” or the “Company”) announced today that the Board of Directors of the Company has appointed Lucibeth N. Mayberry as President and Chief Executive Officer of the Company. Patrick D. Swindle has resigned as President and Chief Executive Officer due to health reasons. Mr. Swindle has served as President and Chief Executive Officer since January 1, 2026, following his appointment as President and Chief Operating Officer on January 1, 2025. In addition, Mr. Swindle resigned from CoreCivic’s Board, and Ms. Mayberry has been appointed to fill the vacancy.

Mr. Swindle said, “It is with a heavy heart that I am announcing my decision to resign as President and CEO of CoreCivic, as I pursue treatment for stage four metastatic pancreatic cancer. It has been the greatest professional honor of my life to serve as President and CEO of this Company. We have an excellent leadership team at CoreCivic, and Lucibeth has been an indispensable member of our executive leadership team, with whom I’ve worked closely for nineteen years on many critical strategic matters for the Company, including the property sales we announced earlier this year. Lucibeth is one of the most capable and principled leaders I know, and I have no doubt that under her stewardship, this Company will continue to grow and make a difference in the lives of the individuals entrusted to our care.”

Ms. Mayberry said, “Patrick is not only a remarkable leader but a valued colleague and a dear friend. I am personally thankful for his mentorship and his numerous contributions to CoreCivic, not just as Chief Executive Officer, but over the course of his many years with the Company. Patrick has been instrumental in leading CoreCivic through a significant period of development and change during his time as President and CEO. I am fully committed to continuing the current capital allocation strategy, maintaining our focus on operational excellence, and look forward to building on the progress already underway.”

Mark Emkes, chair of the Board of Directors, commented, “On behalf of the Board of Directors, I thank Patrick and extend our very best wishes to him and his family. Patrick helped make the Company stronger and more flexible and positioned the Company well for the future. We are profoundly grateful for everything Patrick has given to this organization, and we are honored that he will continue to lend his guidance as a special advisor during this transition. In appointing Lucibeth, the Board is recognizing her significant leadership and the trust she has earned across the organization. She has a deep understanding of our business, a proven ability to execute strategic initiatives, and the full confidence of the Board to lead CoreCivic forward while continuing the strategy that has strengthened the Company and created value for shareholders.”

Ms. Mayberry has served as the Executive Vice President and Chief Strategy Officer since May 2025. From October 2022 to May 2025, Ms. Mayberry served as the Executive Vice President and Chief Innovation Officer. Prior to assuming that role, Ms. Mayberry served as Executive Vice President, Real Estate from May 2015 until October 2022. She has previously served in various roles at CoreCivic since May 2003, including as Vice President, Deputy Chief Development Officer; Vice President, Research, Contract and Proposals; and as Managing Director, State Partnership Relations. Ms. Mayberry holds a bachelor’s degree from the University of Tennessee, a juris doctor from Vanderbilt University, and a Master of Laws degree in taxation from the University of Florida.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements as to our beliefs and expectations of the outcome of future events that are “forward-looking” statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the transition of executive leadership at CoreCivic. These forward-looking statements may include such words as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. Important factors that could cause actual results to differ from our expectations are described in the filings made from time to time by CoreCivic with the Securities and Exchange Commission (“SEC”) and include the risk factors described in CoreCivic’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026 and subsequent filings.

CoreCivic takes no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services, except as may be required by law.

52053606.2

Contact:

Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024
Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Posted on September 25, 2026September 25, 2026 by [email protected]

Research News and Market Data on OCGN

September 25, 2026

PDF Version

Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP) within 90 days, following full approval by the Longevity and Regenerative Therapies Board (LARTA Board)
In partnership with the LARTA Board, Ocugen intends to address global access and unmet need through commercial pricing evidenced with cost-effectiveness for a one-time broad treatment of RP
A novel modifier gene therapy for RP, OCU400 is advancing through Phase 3, with topline data expected in 1Q 2027 and a Biologics License Application submission planned for 2Q 2027

MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that OCU400 has been granted provisional approval and priority designation from the LARTA Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs within the Commonwealth of The Bahamas. Ocugen will supply OCU400 through an EAP, with the goal of treating the first RP patient within 90 days, following full LARTA approval.

“Our partnership marks an important milestone for Ocugen – creating a unique opportunity to provide global access through the Bahamas to OCU400 for people suffering from retinitis pigmentosa,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen. “This landmark collaboration demonstrates the potential of our differentiated gene therapy platform and represents an exciting step toward expanding the reach of our innovative, one-time treatments for patients with serious retinal diseases.”

LARTA Priority Designation
LARTA Priority Designation recognizes the scientific and clinical promise of a program and its potential to address significant unmet medical need. When granted alongside Provisional LARTA Approval, it places the program on a structured pathway of enhanced regulatory engagement and expedited coordination, designed to advance it towards Full Approval, operational readiness and responsible patient access.

About OCU400
OCU400 is a modifier gene therapy candidate, currently in Phase 3, targeting a broad RP indication – from early-to late-stage disease; pediatric to adult patients – and is designed to treat mutations caused by more than 100 genes. It is based on a nuclear hormone receptor gene called NR2E3 which regulates diverse physiological functions within the retina, such as photoreceptor development and maintenance, metabolism, phototransduction, inflammation, and cell survival. Retinal cells in RP patients have a dysfunctional gene network, and OCU400 is designed to reset this network to reestablish a healthy cellular homeostasis. OCU400 has been granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), and Orphan Medicinal Product Designation (OMPD) by the European Medicines Agency (EMA).

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of enrollment and data readouts, the ability to initiate new clinical programs, statements regarding the ability to treat the first patient 90 days after obtaining Provisional LARTA Approval and Priority Designation in The Bahamas, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that receipt of Provisional LARTA Approval and Priority Designation may not lead to faster regulatory review and Full Approval; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contacts:

Investors:
Candice Masse
astr partners
[email protected]

Media:
Chris Clark
[email protected]

Release – Conduent to Host Investor Day on September 30, 2026

Posted on September 24, 2026September 24, 2026 by [email protected]

Research News and Market Data on CNDT

September 24, 2026

Corporate Earnings/Financial

Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced that it will host an Investor Day on Wednesday, September 30, 2026, from 8:25 a.m. ET – 12:30 p.m. ET at The Pierre Hotel in New York City.

Harsha V. Agadi, President and Chief Executive Officer, and members of Conduent’s executive leadership team will provide an overview of the company’s long-term strategy, portfolio priorities and growth opportunities across its markets, followed by a question-and-answer session.

The Investor Day live webcast will be open to the public and will be available at investor.conduent.com . The presentation slides will be posted at investor.conduent.com when the presentation begins, and a replay will be available on the site for 90 days following the event.

The Company may discuss material information at the Investor Day. Presentation materials will be furnished on a Form 8-K and will be available on the site.

About Conduent
Conduent is a global technology-enabled operating partner that helps businesses and governments simplify complexity, modernize mission critical operations and deliver measurable outcomes through AI, automation, data and human expertise. Learn more at www.conduent.com .

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit https://x.com/Conduent , http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent .

Trademarks
Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, including statements regarding the Company’s Investor Day and the long-term strategy, portfolio priorities and growth opportunities to be discussed there. These statements are not guarantees of future performance. They are based on management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties, many of which are outside the Company’s control, that could cause actual results to differ materially from those expressed or implied, including the factors described under Risk Factors in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in its subsequent Quarterly Reports on Form 10-Q, which are available at investor.conduent.com and www.sec.gov . Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
Remy Kaul, Conduent, [email protected]

Investor Relations Contact:
Nick Goel, Conduent, [email protected]

Release – Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

Posted on September 23, 2026September 23, 2026 by [email protected]

Research News and Market Data on NNVC

Wednesday, 23 September 2026 08:30 AM

Topic:

Company Update

SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that the Phase II Clinical Trial of the Company’s Novel Broad-Spectrum Antiviral Drug NV-387 as a Treatment for Monkeypox Virus Infection has begun with enrollment of first patients in the Democratic Republic of Congo (DRC).

This clinical trial was registered in the Pan African Clinical Trials Registry database (pactr.samrc.ac.za). The unique identification number for this clinical trial is PACTR202609506749917.

The clinical trial is entitled: “An adaptive international, multi-center, randomized, open-label, interventional, parallel group, phase II (IIa and IIb) clinical trial to evaluate the efficacy and safety of a new chemical entity NV-387 formulated as oral gummies in comparison to standard of care, administered in patients with clinical signs of mpox disease and laboratory confirmed or presumptive hmpxv infection.”

The Principal Investigator for this clinical trial is Prof. Vivi Maketa Tevuzula, MD, MSc, PhD, Professor in the Department of Tropical Medicine at the University of Kinshasa and Principal Investigator at the Institut Multisectoriel pour l’Amélioration du Bien-être (IMABE), Kinshasa, DRC. Her work focuses on infectious diseases, including clinical trials demonstrating the safety and efficacy of novel drugs, and safety, immunogenicity, and efficacy of vaccines, as well as health systems research in resource-limited settings. She has served as principal investigator on multiple international studies on malaria, Mpox, and vaccine-preventable diseases, and leads interdisciplinary research on genomic surveillance and One Health approaches.

Bayer Foundation awarded Dr. Vivi Maketa with the prestigious Early Excellence in Science Award 2023 in Medical Science, recognizing her exceptional contributions to the design and implementation of research projects on infectious and neglected tropical diseases ⁱ.

“We are pleased to have Professor Maketa lead this clinical trial,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “This is the very first Phase II clinical trial of the broad-spectrum antiviral drug NV-387 and aims to explore its safety and effectiveness in Mpox.”

There is no approved drug for Mpox. Clinical trials of a drug called tecovirimat (TPOXX, SIGA) have previously failed to demonstrate efficacy against both Mpox Clade II and Mpox Clade I. Tecovirimat was approved by US FDA for Smallpox under the Animal Rule provision.

A pan-African clinical trial called “MOSA” of a drug called brincidofovir, which is approved by US FDA for Smallpox under the Animal Rule provision, that started in January, 2025, is currently ongoing. As of January 2026, according to a press release, this study’s Data Safety and Monitoring Board (DSMB) did not identify any new safety concern after the first 50 patients were randomized, and the trial plans to enrol a further 50 patients in the first half of 2026, to perform interim efficacy analysis of brincidofovir ⁱⁱ. Brincidofovir requires constant physician care due to dose-limiting liver and gastro-intestinal toxicity concerns ⁱⁱⁱ.

NV-387 could become the “go to” pandemic response drug if it is successful in this Phase II MPox clinical trial, and becomes a FDA-licensed (approved) drug. US Government SNS stockpiling contracts for existing smallpox drugs TPOXX and TEMBEXA have been in several hundreds of millions of dollars, representing an equivalent potential opportunity for NV-387.

The Phase II clinical trial for NV-387 as a treatment of mpox is being conducted at Lodja in Sankuru province in DRC. As of now, this province is not an ebola-affected region.

Professor Maketa’s team is already on site in DRC. In addition, The team of our CRO from India, Om Sai Clinical Research Pvt. Ltd., is also on site in DRC to start the clinical trial.

Lodja is a remote location and mpox cases are continuing to occur in that area. This is a resource-poor region. Setting up the clinical sites required several months of effort because of the resource limitations at the hospital.

MPox Clade I is endemic in DRC and all cases in the clinical trial are expected to be of the Clade I virus. The other prominent MPox virus, MPox Clade II is substantially less severe an infection than MPox Clade I.

MPox Clade II has become endemic in the USA, circulating at low levels. It primarily affects a limited population of Men-having-Sex-with-Men (MSM), because of transmission during sexual activity.

MPox is an “Orphan Disease” in the USA. NanoViricides has applied to the US FDA for Orphan Drug Designation (ODD) of NV-387 for the treatment of MPox. This ODD, assuming it is granted, would enable several benefits including frequent meetings with FDA, waiver of certain FDA fees, certain R&D credits, as well as extension in exclusivity in marketing once approved.

These ODD benefits can have a positive economic impact for NanoViricides estimated in the range of tens of millions of dollars.

MPox Clade I cases in the USA have been slowly increasing. As of August 27, 2026, since November 2024, there have been more than 50 confirmed cases of Mpox Clade I in the USA, all of which were either travelers to Mpox-manifesting countries or regions, or contacts of such travelers, according to the CDC ^iv. Community spread of the MPXV Clade I is likely occurring, with 3 cases of MPox Clade I with no travel to Africa, in California in unconnected persons, according to the CDC ^v. However, the potential for a widespread outbreak remains low.

From 2023-2025, about 1,700-2,800 cases of Mpox Clade II were confirmed in the USA, mostly occurring in men-having-sex-with men and associated sexual partners, according to the CDC (ibid #4). Clade II is transmitted via skin abrasions.

Thus MPox is becoming important in the USA from the perspective of pandemic preparedness and response. Although there is a vaccine originally developed for smallpox, namely, Jynneos, that is in use to prevent MPox (primarily in clade II contacts), its immune protection was found to wane rapidly in a clinical study ^vi. The effectiveness of this vaccine is limited, at 36% for one dose and 66% for 2 doses against the less pathogenic MPox Clade II ^vii.

The vaccine effectiveness is likely to be much less against the more severe MPox Clade I.

Vaccines do not protect in the first few weeks, limiting their usefulness during pandemic.

We believe that there will be a strong opportunity for NV-387 for pandemic preparedness and response for the threats of Mpox and Smallpox in the USA if this Phase II clinical trial of NV-387 for the treatment of Mpox is successful. The two drugs in the USA Strategic National Stockpile (SNS), TPOXX and TEMBEXA, would be unsuitable for pandemic response if MPox Clade I spreads. Although both of these drugs are approved for Smallpox, a bioterrorism agent, under the FDA animal rule, the clinical trial failure of tecovirimat against Mpox which is a much less severe and far less lethal disease compared to Smallpox raises questions about its possible utility in a Smallpox bioterrorism event. In addition, the known toxicity profile and warnings for brincidofovir make it unsuitable for wide-scale deployment in a large outbreak scenario.

“NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases,” said Anil R. Diwan, Ph.D., adding “NV-387 is designed to mimic human cells to trap and destroy the virus. This single drug can target over 90-95% of human pathogenic viruses due to this biomimicry, which is reminiscent of the antibiotic penicillin that targets a large number of human pathogenic bacteria.”

NV-387 was found to possess strong antiviral activity against an orthopoxvirus in an animal model that is considered an important model to establish potential effectiveness against MPox and Smallpox viruses, as all of these viruses belong to the same family of orthopoxviruses.

In fact, NV-387 effectiveness matched the effectiveness of the small chemical drug tecovirimat in two different models of infection, one was direct skin infection, and the other was a direct lung infection, by the virus.

Escape of virus from tecovirimat is known to occur by a single point mutation in a viral protein called VP-37.

Vaccines, antibodies, and small chemical drugs such as tecovirimat for MPox/Smallpox, or oseltamivir (Tamiflu^®), baloxavir (Xofluza^®) for Influenza are readily escaped by viruses simply by introduction of small changes that viruses undergo when they are faced with these challenges in the field.

In contrast, escape of virus from NV-387 is highly unlikely because no matter how much the virus changes in the field, it continues to use sulfated proteoglycans such as HSPG as “attachment receptor” in order to cause cell infection. NV-387 mimics the sulfated proteoglycan signature feature that the viruses require.

NV-387 is a host-mimetic drug that “looks like a cell” to the virus, displaying numerous ligands that mimic the sulfated proteoglycan, enticing the virus to bind to and become engulfed by the NV-387 dynamic shape-shifting polymeric micelle.

Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug undergoes regulatory development for approval for use in humans.

New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep appearing in time. To combat such threats, we need to develop broad-spectrum drug arsenal that the viruses cannot escape. Vaccines and antibodies simply will not do, and their limitations have become clearly evident during the COVID-19 pandemic.

About NanoViricides

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide^™ class of drug candidates and the nanoviricide^™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

Where stated with an ^® , the name is a registered trademark, which belongs to the owner of the trademark name.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]

Public Relations Contact:
[email protected]

i https://www.bayer-foundation.com/lets-spotlight-our-science-talents-dr-vivi-maketa

ii https://mpx-response.eu/a-first-safety-interim-analysis-of-mosa-shows-no-signal-of-safety-concerns-with-brincidofovir-a-potential-antiviral-to-fight-mpox/

iii According to the drug label (prescribing information), brincidofovir (“TEMBEXA”) carries a black box warning, and has warnings for elevations in hepatic transaminases and bilirubin (liver toxicity) and diarrhea and other gastrointestinal adverse events. Brincidofovir administration must be performed under physician care with continuous evaluation of liver toxicity.

iv https://www.cdc.gov/monkeypox/situation-summary/index.html

v https://www.aha.org/news/headline/2025-10-29-cdc-says-3-cases-severe-mpox-california-may-be-linked-august-case

vi https://www.cidrap.umn.edu/mpox/amid-new-mpox-outbreak-study-suggests-waning-protection-jynneos-vaccine

vii From the Mpox Emergency Response Team, CDC (2023-05) “Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States,” N Engl J Med 2023;388:2434-43.

SOURCE: NanoViricides

Release – MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

Posted on September 23, 2026September 23, 2026 by [email protected]

Research News and Market Data on MAIA

September 23, 2026 9:17am EDT Download as PDF

THIO-104 advances toward key 2027 interim survival analysis

CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for its ongoing pivotal Phase 3 THIO-104 clinical trial in non-small cell lung cancer (NSCLC).

Spain and Portugal represent important European markets for NSCLC, with an estimated 30,000 new cases annually across the two countries. Spain has a substantial lung cancer burden associated with historical tobacco exposure, with lung cancer incidence among women continuing to rise. In Portugal, NSCLC accounts for approximately 82% of lung cancer cases, the highest proportion reported among five European populations evaluated in a comparative study.

“Expanding THIO-104 into Spain and Portugal represents another important step in the execution of our pivotal Phase 3 program,” said Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA. “Clinical trial participation can provide patients with access to investigational therapies in markets where access to newly approved lung cancer treatments has historically lagged. By establishing THIO-104 sites in Spain and Portugal, we are broadening access to a potentially important new treatment option for patients with advanced NSCLC who have progressed following standard of care treatments.”

To date, THIO-104 has enrolled 65 NSCLC patients resistant to chemotherapy and checkpoint inhibitor treatments at 28 clinical sites in 6 European countries and 10 sites in Taiwan. Among the six European countries, sites in Hungary, Poland, and Turkey are actively enrolling and dosing patients from populations with the highest lung cancer incidence and mortality rates in Europe and globally.¹

MAIA targets 100 patients dosed in THIO-104 by year-end 2026 and expects to have sufficient survival data to conduct an interim data analysis in 2027.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]

¹ Sources: Global Cancer Observatory (GLOBOCAN), European Cancer Information System (ECIS), World Cancer Research Fund

Source: MAIA Biotechnology, Inc.

Released September 23, 2026

Release – Xerox Announces Major Production Print Portfolio Expansion at PRINTING United Expo 2026

Posted on September 23, 2026September 23, 2026 by [email protected]

Research News and Market Data on XRX

PDF Version

September 23, 2026

LAS VEGAS–(BUSINESS WIRE)–Sep. 23, 2026– Xerox Holdings Corporation (NASDAQ: XRX) today announced a major production print portfolio expansion as part of PRINTING United Expo 2026, introducing three new press platforms and enhancements to existing presses.

With these introductions, Xerox is deepening its commitment to production print with an inkjet portfolio spanning cut-sheet and continuous-feed, alongside a new 6-color flagship press for graphic arts. Integrated with the Xerox end-to-end production ecosystem of presses, workflow automation software, media expertise and lifecycle services, the new offerings extend specialty color and intelligent automation capabilities across the broader portfolio, helping print providers bring more work in-house, streamline production and pursue new revenue opportunities.

“PRINTING United is the ideal stage to show how Xerox is driving the future of production print,” said Terry Antinora, President, Global Production Print Services at Xerox. “We’re giving print providers a complete inkjet portfolio, embellishment, intelligent automation, and AI-powered tools that help them grow, differentiate, and win. Everything we’re launching is designed to improve customer profitability — not just increase print volume.”

Attendees can explore the following additions to the Xerox production print portfolio:

Xerox^® Proficio™ Jet CS1100: A B3 cut-sheet inkjet press that delivers speeds of up to 300 images per minute. New Xerox-developed printheads and a high-definition ink formulation deliver 1200 × 1200 dots per inch resolution with 2-bit variable-drop imaging for precise dot placement. A scalable drying architecture supports media up to 350 grams per square meter, including coated stocks. The platform enables print providers to shift a wider range of work, from transactional and direct mail to graphic communications and commercial print, onto a single press without compromising quality.
Xerox^® Proficio™ Jet CF1200: An industrial continuous-feed inkjet press that delivers speeds of up to 525 feet per minute at 1200 dpi within a compact 28-foot footprint. The smallest 20-inch press in its class handles between 4 million and 30 million Letter / A4 impressions per month, helping high-volume print providers increase capacity, operate more efficiently and protect margins.
Xerox^® Proficio™ PX700 FLX: A new graphic arts production press that delivers speeds of up to 120 pages per minute and supports up to six colors inline at rated speed. New Fluorescent Green specialty toner further expands the color gamut and improves RGB accuracy when paired with Fluorescent Pink. Intelligent automation helps reduce operator intervention and improve consistency, enabling print providers to create differentiated, high-value applications.
Xerox^® Proficio™ PX300 and PX500 feature updates: Enhanced with new Beyond CMYK and fifth-color options, including Gold, Silver and White, the Proficio PX300 and Proficio PX500 expand opportunities for metallic effects and printing on dark and transparent media. The Proficio PX300 now also features the Xerox^® PredictPrint Media Manager, which uses AI-assisted cloud intelligence to simplify media setup and optimize color stability.

At PRINTING United, Xerox will host demonstrations and discussions on generative AI for specialty print, workflow analytics and automation through Xerox^® FreeFlow^® Core and Xerox^® FreeFlow^® Vision Connect Software, and generative AI, along with business development resources available through the Genesis Initiative. The Xerox Genesis Initiative helps creative teams maximize the value of Beyond CMYK technologies through specialty inks and embellishments, and application development resources.

To learn more, visit Xerox at PRINTING United booth #N6729 or explore the company’s production print portfolio at Xerox.com.

About Xerox Holdings Corporation (NASDAQ: XRX)

Xerox is a global technology company with more than 120 years of innovation leadership. We design, manufacture, deliver, and support print, IT, and digital services for nearly 200,000 clients worldwide. Our integrated, AI-powered portfolio includes managed and production print, document management, workflow automation, cybersecurity, cloud managed services, IT infrastructure and collaboration technology. Serving clients from growing SMBs to 90 percent of the Fortune 500, Xerox supports leading healthcare, government, financial services, education, legal, retail and commercial organizations. Through direct sales and a global network of channel partners, we deliver the technology, expertise, and support organizations need to operate efficiently, securely and at scale.

Note: To receive RSS news feeds, visit www.news.xerox.com. For open commentary, industry perspectives and views, visit www.linkedin.com/company/xerox or www.youtube.com/XeroxCorp.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260923599586/en/

Media Contact
Justin Capella, Xerox, [email protected]

Source: Xerox Holdings Corporation

Release – NN, Inc. Raises Full-Year 2026 Guidance Ranges for Net Sales and Adjusted EBITDA

Posted on September 23, 2026September 23, 2026 by [email protected]

Research News and Market Data on NNBR

PDF Version

CHARLOTTE, N.C., Sept. 22, 2026 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR) a global leader in precision manufacturing, today announced that it is raising its full-year 2026 guidance ranges for Net Sales and Adjusted EBITDA.

Updated Full-Year 2026 Guidance

Metric	Prior Guidance	Updated Guidance
Net Sales	$460 million – $480 million	$470 million – $490 million
Adjusted EBITDA	$55 million – $65 million	$58 million – $68 million

Management’s updated guidance for 2026 Net Sales at midpoint is $480 million, up $58 million, or 14% versus full-year 2025 Net Sales.

Management’s updated guidance for 2026 Adjusted EBITDA at midpoint is $63 million, up $14 million, or 29% versus full-year 2025 Adjusted EBITDA.

Chief Executive Officer Harold Bevis commented, “Our business continues to build momentum as we ramp up in our key growth markets of Data Center, Defense & Electronics, and Medical, where demand for our solutions remains strong and actively expanding. Our year-to-date results and year-to-go forecast underpin this improved guidance and reflect the steady performance our growth and cost programs.

NN is continuing to invest forward in its 5 Pillar growth end markets and this is translating to increased success and higher results. Raising our full-year 2026 guidance for net sales and adjusted EBITDA reflects our confidence in the performance of the business. We remain focused on our balanced plans for delivering profitable growth and improved cost productivity for our customers and shareholders.”

NN, Inc. will provide additional detail and updated guidance when it reports third quarter 2026 results on October 28, 2026.

About NN, Inc.
NN, Inc. (NASDAQ: NNBR) is an entrepreneurial manufacturing company specializing in manufacturing micron-toleranced precision metal componentry for high-growth end markets, especially Data Center, Electric Grid, Medical, Defense, and High-Value Vehicle systems. Founded in 1980, NN serves over 700 customers on 4 continents through its 2,550 person workforce operating out of 27 global plants. This footprint enables rapid innovation and global scaled solutions. For more information, visit nninc.com.

Forward Looking Statements
This press release may contain forward-looking statements regarding our business, operations, and financial performance. Such statements are based on current expectations and assumptions that are subject to a number of risks and uncertainties. Actual results could differ materially. Please refer to our most recently filed Form 10-K and our Form 10-Q for the period following that Form 10-K, including the risk factors described therein. We undertake no obligation to update any forward-looking statement, except as required by law. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.

This press release contains certain financial measures not presented in accordance with U.S. generally accepted accounting principles (“GAAP”) such as adjusted EBITDA (the “non-GAAP financial measures”). These non-GAAP financial measures are not calculated in accordance with GAAP and should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures, and may not be comparable to similarly titled measures used by other companies. Management uses these non-GAAP financial measures, together with the comparable GAAP measures, to evaluate the Company’s operating performance and underlying business trends across periods on a consistent basis, and to assist in operational and financial decision-making, including with respect to internal budgeting and resource allocation. Reconciliations of each non-GAAP financial measure to its most directly comparable GAAP measure are set forth in the tables accompanying this presentation. A reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures is not provided because the Company cannot reasonably predict certain items necessary for such reconciliation without unreasonable efforts.

Investor Relations:
Joe Caminiti
[email protected]
312-445-2870

Release – Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on NTRB

GlobeNewswire

Tuesday, September 22, 2026, 8:00:00 AM EDT

ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled. The Company will not extend the expiration date and will not reprice the warrants.

Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. Warrants not exercised by that date will expire in their entirety and be removed from the NTRBW Nasdaq listing.

There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds to the Company if fully exercised at the $6.43 strike price.

Key dates and terms:

Expiration date: September 30, 20265PM ET
Strike price: $6.43 per warrant
Warrants outstanding: 910,904
No extension. No repricing.

Shareholders and warrant holders are advised to act before the deadline if they intend to exercise. Nutriband will continue to provide updates on Company developments in the coming weeks.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: [email protected]

Source: Nutriband Inc.

Release – Power Metallic Extends Lion 25% Deeper as Power Metallic Intercepts 5.70 Meters of 14.00% CuEqRec¹ in Hole 26-125

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on PNPF

Sep 22, 2026

TORONTO, Sept. 22, 2026 – Power Metallic Mines Inc. (the “Company” or “Power Metallic”) (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1) is pleased to provide the first assays of extensional deep drilling of assay results from its Summer 2026 drill program. Prior to the summer drill program drilling concentrated on improving the density of drill intercepts for the recently announced MRE to increase the confidence of modelling Lion, particularly within the range of a potential future open pit, and to bring the vast majority of the known deposit as of the end of the winter program (end April 2026) to Drill Indicated category.

For the summer drill program Power Metallic has carried out widely spaced exploration drilling on geological and geophysical (EM) targets and more importantly begun a program of extending the Lion deposit to depth below the outline of the MRE model. The two holes reported here are the first assays to be completed on this deep drilling.

Hole PML-26-125 is the deepest assay results to date at Lion at a vertical depth of nearly 800m vertical depth, well below the current MRE. Prior to Hole PML-26-125 The deepest reported hole intersecting the core of the Lion shoot to date (PML-25-002) intersected 1.95 metres at 7.95% CuEqRec* at approximately 610 metres vertical depth. This hole was targeted on the projected center of the Lion plunge approximately 150m below the previous deepest hole and intersected 5.7m of massive to semi-massive copper sulphides (Table 1). An earlier drill hole, PML-26-121a targeted the western side of the projected plunge of Lion at a vertical depth of nearly 650 meters and intersected disseminated to semi-massive copper sulphides. A subsequent hole (PML-26-128) tested the eastern side of the interpreted Lion plunge at nearly 900 meters vertical depth, showing disseminated and massive veinlets of copper sulphides, with assays pending (Figure 1). All three of these holes firmly established that the Lion deposit continues at depth and has not been fully delineated.

Table 1: Lion Results – Summer 2026
Hole	From	To	Length	Au	Ag	Cu	Pd	Pt	Ni	CuEq Rec*
Hole	(m)	(m)	(m)	(g/t)	( g/t )	( %)	(g/t)	(g/t )	( %)	( %)
PML-26-121a	666.30	674.00	7.70	0.26	18.42	1.03	3.70	0.28	0.14	3.28
Including	666.30	671.00	4.70	0.35	28.37	1.51	6.45	0.45	0.14	4.92
Including	666.30	668.00	1.70	0.66	72.41	3.34	16.25	1.21	0.16	11.93
PML-26-125	845.80	851.50	5.70	0.30	61.57	11.42	2.48	0.26	0.41	14.00
Including	846.70	848.85	2.15	0.55	92.04	20.30	4.72	0.51	0.60	24.62

1Copper Equivalent Rec Calculation (CuEqRec1)

CuEqRec represents CuEq calculated based on the following metal prices (USD) : 2,360.15 $/oz Au, 27.98 $/oz Ag, 1,215.00 $/oz Pd, 1000.00 $/oz Pt, 4.00 $/lb Cu, 10.00 $/lb Ni and 22.50 $/lb Co., and recovered grades based on recent locked-cycle metallurgical recoveries by SGS Canada Inc (see press release Jan 21, 2006).
2 Reported length is downhole distance; true width based on model projections is estimated as 85% of downhole length

Figure 1 – Lion Deep Drill holes reported in this news release overlain on Lion zone MRE models (X-Section) and MRE block model (Long Section) with hole locations related to potential plunge extension below MRE models)

Power Metallic is expecting more assay results from the Lion deep drilling and regional exploration in the weeks to come.

Terry Lynch, CEO of Power Metallic, commented:
We are in the unique position due to the high grade and near surface nature of our project to advance development of what the world needs in Critical Minerals, namely Copper and PGEs, but also continue our multifaceted exploration approach to allow the resource to grow substantially between now and the end of 2027. Today’s results pushed us over 25% deeper than the deepest hole used in our recently announced MRE and it did so with significantly higher grades. We have visibility down over 50% deeper and visibly it looks like we are still in the Lion Zone. As we have seen with the great hit Talon Metals recently had deposits can get thicker and richer at depth. The blessing in Lion is our mineralization starts at surface and extends down making it very economic to mine and explore. We are excited to get back to exploration!

Qualified Person

Joseph Campbell, P. Geo, VP Exploration at Power Metallic, is the qualified person who has reviewed and approved the technical disclosure contained in this news release.

About Power Metallic Mines Inc.

Power Metallic is a Canadian exploration company focused on advancing the Nisk Project Area (Nisk–Lion–Tiger)—a high–grade Copper–PGE, Nickel, gold and silver system—toward Canada’s next polymetallic mine.

On 1 February 2021, Power Metallic (then Chilean Metals) secured an option to earn up to 80% of the Nisk project from Critical Elements Lithium Corp. (TSX–V: CRE). Following the June 2025 purchase of 313 adjoining claims (~167 km²) from Li–FT Power, the Company now controls ~330 km² and roughly 50 km of prospective basin margins.

Power Metallic is expanding mineralization at the Nisk and Lion discovery zones, evaluating the Tiger target, and exploring the enlarged land package through successive drill programs. Beyond the Nisk Project Area, Power Metallic indirectly has an interest in significant land packages in British Columbia and Chile, by its 50% share ownership position in Chilean Metals Inc., which were spun out from Power Metallic via a plan of arrangement on February 3, 2025.

It also owns 100% of Power Metallic Arabia which owns 100% interest in the Jabul Baudan exploration license in The Kingdon of Saudi Arabia’s Jabal Said Belt. The property encompasses over 200 square kilometres in an area recognized for its high prospectivity for copper gold and zinc mineralization. The region is known for its massive volcanic sulfide (VMS) deposits, including the world-class Jabal Sayid mine and the promising Umm and Damad deposit.

For further information, readers are encouraged to contact:
Power Metallic Mines Inc.
The Canadian Venture Building
82 Richmond St East, Suite 202
Toronto, ON

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

QAQC and Sampling

GeoVector Management Inc (“GeoVector”) is the Consulting company retained to perform the actual drilling program, which includes core logging and sampling of the drill core.

All core in this news release is either HQ or NQ sized core. Drill core is re-fitted and measured. Geotech on core includes photographs (wet & dry), rock quality index, magnetic susceptibility, conductivity, and recovery estimates. Core is logged for lithology, mineralogy, and structural features, and sample intervals are delineated and tagged.

Sampled core is mechanically sawn, and half-core is retained for future reference. GeoVector’s QAQC program includes regular insertion of CRM standards, duplicates, and blanks into the sample stream with a stringent review of all results. QAQC and data validation was performed, and no material errors were observed.

All samples were submitted to and analyzed at Activation Laboratories Ltd (“Actlabs”), a commercial laboratory independent of Power Metallic with no interest in the Project. Actlabs is an ISO 9001 and 17025 certified and accredited laboratories. Samples submitted through Actlabs are run through standard preparation methods and analysed using RX-1 (Dry, crush (< 7 kg) up to 80% passing 2 mm, riffle split (250 g) and pulverize (mild steel) to 95% passing 105 μm) preparation methods, and using 1F2 (ICP-OES) and 1C-OES – 4-Acid near total digestion + Gold-Platinum-Palladium analysis and 8-Peroxide ICP-OES, for regular and over detection limit analysis. Pegmatite samples are analyzed using UT7 – Li up to 5%, Rb up to 2% method. Actlabs also undertake their own internal coarse and pulp duplicate analysis to ensure proper sample preparation and equipment calibration.

Cautionary Note Regarding Forward-Looking Statements

This message contains certain statements that may be deemed “forward-looking statements” concerning the Company within the meaning of applicable securities laws. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” “indicates,” “opportunity,” “possible” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, are subject to risks and uncertainties, and actual results or realities may differ materially from those in the forward-looking statements. Such material risks and uncertainties include, but are not limited to, among others; the timing for various drilling plans; the ability to raise sufficient capital to fund its obligations under its property agreements going forward and conduct drilling and exploration; to maintain its mineral tenures and concessions in good standing; to explore and develop its projects; changes in economic conditions or financial markets; the inherent hazards associates with mineral exploration and mining operations; future prices of nickel and other metals; changes in general economic conditions; accuracy of mineral resource and reserve estimates; the potential for new discoveries; the ability of the Company to obtain the necessary permits and consents required to explore, drill and develop the projects and if accepted, to obtain such licenses and approvals in a timely fashion relative to the Company’s plans and business objectives for the applicable project; the general ability of the Company to monetize its mineral resources; and changes in environmental and other laws or regulations that could have an impact on the Company’s operations, compliance with environmental laws and regulations, dependence on key management personnel and general competition in the mining industry.

Release – MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on MAIA

September 22, 2026 8:47am EDT

Download as PDF

Strong pace of patient enrollment supports continued advancement toward regulatory milestones

Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLC

CHICAGO, Sept. 22, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that enrollment has reached 65 patients in its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). The THIO-104 trial currently has 38 trial sites activated in 6 foreign countries (Taiwan, Romania, Turkey, Georgia, Poland and Hungary).

“Reaching 65 randomized patients marks an important milestone in our Phase 3 trial. With additional clinical sites expected to begin enrolling patients, we remain on track to achieve our goal of more than 100 randomized patients by year-end,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “As we’ve stated previously, statistical assessments of the Phase 3 trial point to a very high probability of technical success for regulatory approval of ateganosine.¹ We believe third-line NSCLC is an excellent market entry segment due to the substantial unmet medical need in this large immunotherapy-resistant and chemotherapy-resistant population. No current standard of care exists in this NSCLC treatment setting and competition for clinical trial patients is limited.”

In its most recent assessment, ateganosine sequenced with a checkpoint inhibitor showed 90.5% interim disease control rate (DCR) in heavily pretreated 3L NSCLC in MAIA’s ongoing phase 2 THIO-101 clinical trial. This measure contrasts with reported 25%–35% DCRs for standard third-line chemotherapy regimens.

In July 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for ateganosine for the treatment of NSCLC. This designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. If approved, ateganosine will hold FDA New Chemical Entity (NCE) five-year marketing exclusivity. An NCE is a small molecule drug with a novel active ingredient that hasn’t been previously approved or marketed.

About Ateganosine

About MAIA Biotechnology, Inc.

About THIO-104 Phase 3 Clinical Trial

THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. For more information on this Phase 3 trial, please visit ClinicalTrials.gov using the identifier NCT06908304.

Forward Looking Statements

Investor Relations Contact
+1 (872) 270-3518
[email protected]

¹ See latest MAIA investor presentation and 2026 shareholder letter at ir.maiabiotech.com/company-information/presentations.

Source: MAIA Biotechnology, Inc.

Released September 22, 2026

Release – Century Lithium Advances Plans for Chlor-Alkali Plant

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on CYDVF

Plans Support Critical Minerals Supply Chain and Company’s Angel Island Lithium Project;
Eight Offtake MOUs Signed for Chlor-Alkali Products

September 22, 2026 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) is pleased to announce its plans to develop a commercial-scale chlor-alkali plant (“CA Plant”). The CA Plant is intended to support the critical and strategic minerals supply chain in the Western United States and the Company’s 100%-owned Angel Island Lithium Project (“Angel Island” or the “Project”) in Esmeralda County, Nevada, USA, currently in the permitting phase.

“In the course of our work on Angel Island, Century Lithium identified chlor-alkali products as a fundamental component of the critical minerals supply chain,” said Bill Willoughby, President and CEO of Century Lithium. “We also recognized a regional opportunity in the Western U.S. for a plant producing these products. The proposed CA Plant has the potential to generate revenue on its own, train an operating team and reduce future reagent supply risk to Angel Island. Century Lithium has evaluated a number of potential sites for the CA Plant in Nevada and Utah that could meet its criteria for proximity to infrastructure and resources and expects to finalize a selection shortly. The Company has obtained non-binding offtake interest for production from the CA Plant from a number of companies and is actively pursuing project-level financing.”

Highlights

Chlor-alkali products are essential inputs across the critical minerals supply chain, supporting lithium and battery-materials processing, rare earth element separation, and precious and specialty metals production, in addition to broader industrial and household uses.
The proposed CA Plant would produce chlorine, hydrochloric acid and sodium hydroxide from sodium chloride, water and electricity, at a target commercial production rate of 300 short tons per day (“st/d”) of chlorine, with provision to double capacity to 600 st/d depending on regional demand and the supply needs of Angel Island.
Century Lithium has entered into eight non-binding Memoranda of Understanding (“MOU”) with third parties for offtake arrangements that could collectively account for the full initial production of the proposed CA Plant.
Candidate sites in Nevada and Utah were evaluated against feedstock, power, rail access, market proximity, land tenure, and permitting criteria.
The proposed CA Plant would use modern, proven technology in a location favorable for infrastructure development.
Site due diligence is underway; the next step will be securing project-level financing to fund property acquisition, front-end engineering and design (“FEED”) and permitting of the selected site.

Site Selection

The Company is in the process of selecting the preferred site for the CA Plant out of a number of candidate sites which included a combination of private industrial land, state land, and federally controlled land available under lease.

The site selection process has considered internal engineering and economic work and studies addressing equipment selection, power, water and sodium chloride supply, CA product handling and comparative site economics.

Relation to Angel Island

The Feasibility Study for Angel Island (Updated NI 43-101 Technical Report on the Feasibility of the Clayton Valley Lithium Project, Esmeralda County, Nevada, USA, January 3, 2026) includes an on-site chlor-alkali plant as the base case for the Project. The capital and operating estimates disclosed in the Feasibility Study are unchanged by this announcement. The proposed CA Plant in this announcement does not replace that facility, and none of its cost is added to Angel Island.

The economics of the proposed CA Plant are based solely on internal study and the assumption of commercial sales of all chlor-alkali products to third-party customers. No revenue, cost saving or capital credit associated with Angel Island is included in them, and the CA Plant is intended to be financed at the project level.

The supply of reagents from the proposed CA Plant to Angel Island would depend on the economics of transportation still to be determined. Century Lithium views the proposed CA Plant as a self-funding first step toward Angel Island rather than a change in the Company’s lithium strategy.

Offtake and Commercial Arrangements

Century Lithium has entered into eight non-binding MOUs with companies in various industrial and chemical sectors in the Western U.S. to supply them with chlorine, hydrochloric acid, and sodium hydroxide produced by the proposed CA Plant. The Company is also in discussions with other prospective purchasers of these products.

Project Financing

Century Lithium intends to finance the proposed CA Plant through non-dilutive financing at the project level. The capital structure under evaluation contemplates a combination of vendor financing associated with site acquisition, institutional preferred equity, prepayments and similar support from offtake counterparties, and non-dilutive United States government programs that may be available to domestic critical minerals and industrial capacity. The Company has engaged financial advisors and has commenced consultations with United States government financing agencies. Land acquisition and front-end engineering are expected to be funded first, with construction financing arranged following completion of FEED and definitive offtake agreements.

Century Lithium’s objective in structuring the proposed CA Plant separately is to fund it with capital appropriate to an industrial chemical asset with anticipated offtake, and to limit dilution to shareholders of Century Lithium. No financing has been secured at this time, and no definitive agreements have been entered into, and there is no assurance that financing will be available on acceptable terms or at all.

Next Steps

Due diligence is underway and includes property negotiations, project-level funding, and investigation of power supply terms with the serving utility, salt feedstock and transportation, water rights, land tenure and title, environmental condition, and the permitting pathway. Once the preferred site is selected and secured, the Company intends to advance the preferred site to FEED with a qualified engineering, procurement and construction contractor and to commence permitting, while continuing discussions with prospective commercial counterparties and sources of project financing. Long-lead electrical equipment is a recognized schedule constraint for United States chlor-alkali projects, and the Company is evaluating equipment sourcing in parallel with site selection.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced-stage lithium development company focused on its 100%-owned Angel Island Lithium Project in Esmeralda County, Nevada. Angel Island hosts one of the largest known sedimentary lithium deposits in the United States and is designed with an integrated, end-to-end process to produce battery-grade lithium carbonate on-site to support the electric vehicle and battery storage markets.

The Company has developed a patent-pending process that incorporates hydrochloric acid leaching combined with direct lithium extraction to produce battery-grade lithium carbonate. As part of the integrated chlor-alkali process, Angel Island is designed to produce sodium hydroxide as a co-product, with planned surplus sales expected to lower operating costs, reduce reliance on externally sourced reagents, and minimize environmental impacts.

Century Lithium is currently advancing Angel Island through the permitting process.

Century Lithium trades on the TSX Venture Exchange under the symbol “LCE” the OTCQX under the symbol “CYDVF” and on the Frankfurt Stock Exchange under the symbol “C1Z”.

To learn more, please visit centurylithium.com.

ON BEHALF OF CENTURY LITHIUM CORP.

WILLIAM WILLOUGHBY, PhD, PE
President & Chief Executive Officer
For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
[email protected]
centurylithium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” and similar expressions suggesting future outcomes or statements regarding an outlook.

Forward-looking statements relate to any matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, without limitation, statements with respect to the potential development of a chlor-alkali plant, site selection, anticipated capacity and product slate, regional supply and demand conditions, and the intended financing structure and sources for the chlor-alkali plant, the anticipated benefits of the plant to the Angel Island Lithium Project, and anticipated engineering, permitting and financing activities and their timing. Forward-looking statements are based on assumptions management considers reasonable, including as to the availability of a suitable site, power, feedstock, permits, equipment and financing on acceptable terms, and as to regional demand. Actual results may differ materially. The Company has not made a construction decision, has not secured a site, and there is no assurance that any plant will be developed or that any memorandum of understanding will result in a definitive agreement. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update them except as required by law.

These and other forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. These risks include those described under the heading “Risk Factors” in the Company’s most recent annual information form and its other public filings, copies of which can be found under the Company’s profile at www.sedarplus.ca. The Company expressly disclaims any obligation to update forward-looking information except as required by applicable law. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place reliance on forward-looking statements or information. Furthermore, Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

Release – Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on ELDN

September 22, 2026

PDF Version

Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24

No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm

Tegoprubart granted U.S. FDA Fast Track designation for the prevention of rejection in kidney transplantation

Phase 3 LEGACY study expected to initiate in the fourth quarter of 2026

IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced updated long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney transplantation, presented at the International Congress of The Transplantation Society, taking place September 20-23, 2026, in Sydney, Australia. The Company also announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to tegoprubart for the prevention of rejection in kidney transplantation.

“The BESTOW extension study data and continued improvements in kidney function and safety profile with tegoprubart versus standard of care tacrolimus further strengthen our belief in tegoprubart’s potential to become the new cornerstone immunosuppression therapy for kidney transplant recipients,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “These long-term results, together with FDA Fast Track designation, support our plans to initiate the Phase 3 LEGACY study in kidney transplantation in the fourth quarter and advance tegoprubart as quickly as possible for transplant patients in need of better immunosuppressive options to improve long-term outcomes.”

The FDA’s Fast Track process is designed to facilitate the development and expedite the review of drugs that treat serious conditions and address significant unmet medical needs. Companies receiving Fast Track designation may be eligible for more frequent interactions with the FDA, rolling review of future marketing applications, and eligibility for Accelerated Approval and Priority Review.

Figure 1: Patients who completed treatment were those who completed 52 weeks of the study and received all planned doses of the randomized study drug. Data for M15 onward were collected from patients who completed treatment and enrolled in BESTOW EXTENSION. *p < 0.05 (treatment difference at M18, M21 and M24). Data extraction date: 31 Aug 2026. CI, confidence interval; eGFR, estimated glomerular filtration rate; M, Month; SEM, standard error of the mean; tac, tacrolimus; tego, tegoprubart.

Updated Phase 2 BESTOW Results

As of the data cutoff in the BESTOW long-term extension study, 90 patients had been followed through 18 months, and 81 patients had been followed through 24 months. Tegoprubart-treated patients maintained statistically significantly higher mean estimated glomerular filtration rate (eGFR), a measure of kidney graft function, at months 18, 21, and 24, with an approximately 13 mL/min/1.73 m² advantage over tacrolimus at month 24 (71 vs. 58 mL/min/1.73 m² [95% CI: 2.6, 23.3]). See Figure 1.
There were no reported cases of biopsy-proven acute rejection (BPAR) in the tegoprubart arm beyond six months post-transplant compared with seven in the tacrolimus arm. One new case of graft loss was observed in the tacrolimus arm.

Next Steps

Following its successful End-of-Phase 2 meeting with the FDA, Eledon remains on track to initiate its global Phase 3 trial of tegoprubart in kidney transplantation (LEGACY) in the fourth quarter of 2026. The LEGACY trial is expected to enroll approximately 600 patients, with a primary endpoint of non-inferiority of tegoprubart versus tacrolimus on a composite efficacy failure endpoint at 12 months, defined as a combination of biopsy-proven acute rejection (BPAR), graft loss, and death.

Details of the oral presentation at the International Congress of The Transplantation Society are below:

Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evaluating the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection
Presenter: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
Session Title: Novel immunosuppression
Session Date and Time: Tuesday, September 22, 2026, from 8:00 a.m. to 9:00 a.m. AEST
Session Room: Room C4.9
Presentation Time: 8:00 a.m. AEST

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; X

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Specifically, our ability to achieve our anticipated future development and corporate milestones depends on our ability to obtain additional financing on acceptable terms. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to maintain proper and effective internal control over financial reporting and other risks disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our Annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
[email protected]

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
[email protected]

Source: Eledon Pharmaceuticals, Inc

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/48a2ff2b-c346-426c-a886-6377e5c48d1a

Release – Titan International Signs Definitive Agreement to Sell ITM Business to USCO S.p.A.

Posted on September 21, 2026September 21, 2026 by [email protected]

Research News and Market Data on TWI

Sep 21, 2026

Transaction expected to generate up to approximately $285 million in total cash value

WEST CHICAGO, Ill., Sept. 21, 2026 /PRNewswire/ — Titan International, Inc. (NYSE: TWI) (“Titan” or the “Company”), a leading global manufacturer of off-highway wheels, tires and undercarriage products, today announced that it has entered into a definitive agreement to sell its Italtractor ITM undercarriage business (“ITM”) to USCO S.p.A. (“USCO”).

Under the terms of the agreement, Titan will receive an initial purchase price of $207 million, plus the opportunity to receive an additional $6 million in earnout proceeds based on ITM’s achievement of specified performance criteria for 2026. The transaction is also subject to customary adjustments based on ITM’s specified net asset and financial position at closing, which Titan currently expects will provide approximately $23 million of additional cash value. In connection with the transaction, Titan has received or expects to receive $49 million in dividends from ITM, consisting of $38 million received in recent years and $11 million expected prior to closing. Taken together, these amounts are expected to provide Titan with up to approximately $285 million in total cash value, including the potential earnout.

For Titan, the transaction will allow the Company to sharpen its strategic focus on its core global wheel and tire operations serving the agricultural, construction and consumer markets. It will also significantly strengthen Titan’s financial position and provide greater flexibility to invest behind the Company’s highest-priority growth opportunities.

“It has been approximately ten (10) years since I left the President/CEO position to Paul Reitz and forty-three (43) years since Titan started with no employees and no sales. So, you might say I have seen a lot. The potential sale of ITM was first discussed with Titan’s Board of Directors over ten (10) years when Titan was approached with an offer of less than $100 million. The deal Paul and his team completed has required a lot of patience and I know I could not have gotten this deal done because I do not have that level of patience. This deal is good for Titan and good for USCO. TWI received a fair price, and USCO will now have a strong track manufacturing business with a good brand and great people.

Looking back a decade ago, the primary task for me was finding my replacement. Well, there is no doubt I chose the right man! Paul has led this team for over ten (10) years and done an excellent job. The last ten (10) years have been tough, but as President Trump said we are going into the Golden Age. India has been flooding our country with offroad tires and wheels using unfair practices as we have proven with the International Trade Commission. President Trump is focused on bringing back manufacturing to the USA, but it’s a difficult situation in our industry that requires people understanding real manufacturing of converting raw materials into finished products. I feel that the White House sometimes loses its way with financial people having too much of a say and not enough people that understand real manufacturing.

Our Board of Directors feels there are good opportunities out there to utilize the sale proceeds to explore the purchase of other businesses. TWI has a very bright future because of the depth of our product portfolio and manufacturing footprint. Titan is the world leader in both wheels and tires in the farm industry and let’s not forget the decades of investment we have made with technical engineering and tooling into the large Ag wheels and tires that we produce. Our innovation pipeline of new products has been strong in recent years for farm, industrial and consumer products, and we have been achieving this at competitive cost levels for our customers at the same time.

I am inflating my own ego, because of what Paul and his team pulled off with this transaction and how good I feel that Titan is entering the Golden Age of manufacturing. Paul has also put a group in TWI to make a push into Defense business. Which could be very large for Titan in the next few years. I am betting most of you reading this did not know that TWI made the first aluminum wheels for auto/pickup in the early 90’s. Today 100% of vehicle/passenger wheels are made in China, India and Japan. That means all cars and pickups could be stopped without wheels in USA! 80 million wheels each year are imported. That is $8 Billion dollars each year in income. Yes, I believe the Golden years are ahead, and TWI has proven leadership in Paul Reitz and his team. As the Pointer Sisters song goes ‘I’m so excited’ – that’s me an old man.

The last acquisition that Titan made was the Carlstar Group Wheels & Tires. So far, it has proven to be a really good deal. I should also mention that over the last few years, TWI has bought back over $100 million shares of TWI Common Stock with its cash flow. Paul’s team has done an excellent job. I hope the Golden Age of Manufacturing comes to the USA for TWI has the capacity to easily double production in wheels and tires. There are very few in this world that could make that statement. Thank you for taking the time to read this note.

In conclusion, I want to thank Cecilia La Manna for her invaluable service and many contributions to ITM and Titan. I’ve known Cecilia for nearly 30 years, and I’ve watched her grow into an incredible global business leader. Her determination and commitment is a significant reason why ITM is the business that it is today. USCO is getting much more than a good business and plants, they are getting a strong management team. Cecilia and her team will continue to do great things for USCO and lead them well into a prosperous future.

If you are ever in Illinois – Quincy or Freeport; Tennessee – Union City or Clinton; Bryan, Ohio, Sao Paulo, Brazil, Kidderminster, UK; Meizhou, China and Finale Emilia (list locations), I invite you as a Shareholder to stop in and see how our products are made.

— Maurice M. Taylor, Jr., Chairman of Titan’s Board of Directors

“This transaction is an important step forward in Titan’s transformation. We have worked hard to reach an agreement that delivers strong value for Titan and provides ITM with an owner that understands the undercarriage business and is committed to its future. The transaction will allow Titan to focus our people, capital and resources on our core global wheel and tire operations while giving us the financial capacity to pursue accretive growth opportunities and reduce debt. This transaction helps Titan to reshape its portfolio, accelerate strategic investments, pursue transformative acquisitions and partnerships, and create long-term value for our shareholders.”

— Paul Reitz, President and Chief Executive Officer of Titan

The transaction represents an important strategic step for both organizations. As part of USCO, ITM will have the opportunity to build on its position as a global provider of undercarriage components and complete undercarriage solutions, with additional focus and resources to support long-term growth, customer service, product innovation and geographic expansion. ITM designs, manufactures and distributes undercarriage systems and components for construction, mining, forestry, road-building and agricultural applications through a global manufacturing and distribution network.

Titan currently intends to use a portion of the transaction proceeds to reduce existing debt and strengthen its balance sheet. In future periods, the Company also expects to deploy capital toward key growth investments, including accretive acquisitions and strategic partnerships that expand Titan’s capabilities, strengthen its market positions and support the Company’s long-term transformation.

The transaction is expected to close early in January 2027, subject to the satisfaction of customary closing conditions, including required regulatory approvals and other customary conditions. Until closing, ITM and Titan will continue to operate in the ordinary course of business. The parties anticipate completion shortly following receipt of all required regulatory approvals.

Titan and ITM were advised by the law firm Gianni & Origoni on legal matters and by Poggi & Associati on tax matters. USCO has been assisted by Eidos Partners as financial advisor, by the law firm Simmons+Simmons and by BDO and KPMG as due-diligence consultants

ITM is a global designer, manufacturer and service provider of undercarriage components and complete undercarriage solutions. The business serves original equipment and aftermarket customers across construction, mining, forestry, road-building, agricultural and other specialized applications through an international manufacturing, service and distribution network. ITM is also a pioneer in undercarriage sensor technology, including its TRUST ITM® monitoring solution.

About Titan International, Inc.

Titan International, Inc. (NYSE: TWI) is a leading global manufacturer and supplier of wheels, tires and undercarriage products for a wide variety of off-the-road equipment. Titan serves aftermarket dealers and original equipment manufacturers across the agricultural, earthmoving, mining, construction and consumer sectors.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the expected closing of the transaction, the anticipated purchase-price adjustments and earnout payment, the total value expected to be realized by Titan, the intended use of proceeds, debt reduction, potential acquisitions and partnerships, future investments, and the expected benefits of the transaction to Titan and ITM. These statements are based on Titan’s current expectations and are subject to risks and uncertainties that could cause actual outcomes to differ materially.

These risks and uncertainties include, among others, the ability to obtain required regulatory approvals and satisfy other closing conditions; the timing or failure of the transaction to close; changes in ITM’s net financial or asset position; ITM’s ability to achieve the performance criteria associated with the earnout; foreign-exchange-rate fluctuations; Titan’s ability to reduce debt or identify and complete attractive acquisitions, partnerships or investments; and other risks described in Titan’s filings with the Securities and Exchange Commission. Titan undertakes no obligation to update any forward-looking statement except as required by law.

Exchange-rate note: U.S. dollar amounts are approximate and were translated using an exchange rate of €1.00 to $1.148 as of September 18, 2026.

View original content to download multimedia:https://www.prnewswire.com/news-releases/titan-international-signs-definitive-agreement-to-sell-itm-business-to-usco-spa-302884962.html

SOURCE Titan International, Inc.